statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Kymera Therapeutics Surges 23.4%: Is This an Indication of Further Gains?

Kymera Therapeutics, Inc. (NASDAQ: KYMR) shares ended the last trading session 23.4% higher at $39.44. The jump came on an impressive volume with a higher-than-average number of shares changing hands...

Hold Rating on Kymera Therapeutics Amid Positive Phase II Expansion and Lingering Uncertainties

Kymera Therapeutics (KYMR Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Vikram Purohit f...

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug

Chesnot / Getty Images

 Key TakeawaysKymera Therapeutics shares soared Tuesday, a day after it said partner Sanofi agreed to expand research into its experimental treatment for skin diseases.The...

Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews

Latest Ratings for KYMR
 DateFirmActionFromTo Mar 2022JP MorganInitiates Coverage OnNeutral Mar 2022Morgan StanleyMaintainsEqual-Weight Feb 2022Wells FargoInitiates Coverage OnOverweight
 View...

Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $39.89

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve analysts that are presently covering the company, MarketBeat...

Clear Harbor Asset Management LLC Takes $255,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Clear Harbor Asset Management LLC bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with...

Analyzing Kymera Therapeutics (NASDAQ:KYMR) & Turnstone Biologics (NASDAQ:TSBX)

Turnstone Biologics (NASDAQ:TSBX  Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR  Get Free Report) are both medical companies, but which is the better stock? We will compare the...

Insider Selling: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Major Shareholder Sells $4,860,250.70 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR  Get Free Report) major shareholder Venture Fund X. L.P. Atlas sold 115,090 shares of the companys stock in a transaction on Wednesday, March...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Major Shareholder Venture Fund X. L.P. Atlas Sells 42,302 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR  Get Free Report) major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the stock in a transaction that occurred on Monday, March 11th. The...

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Volume	390,279.00
52-Wk High	$48.70
52-Wk Low	$9.60

KYMR Kymera Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals